National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 10370 [2017-02723]
Download as PDF
<![CDATA[
10370
Federal Register / Vol. 82, No. 27 / Friday, February 10, 2017 / Notices
regard to whether the countermeasure is
used by or administered to this
population; liability immunity is
afforded to program planners and
qualified persons when the
countermeasure is used by or
administered to this population, or the
program planner or qualified person
reasonably could have believed the
recipient was in this population.
XI. Geographic Area
42 U.S.C. 247d–6d(a)(4), 247d–
6d(b)(2)(D)
Liability immunity is afforded for the
administration or use of a Covered
Countermeasure without geographic
limitation.
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered in any
designated geographic area; liability
immunity is afforded to program
planners and qualified persons when
the countermeasure is used by or
administered in any designated
geographic area, or the program planner
or qualified person reasonably could
have believed the recipient was in that
geographic area.
XII. Effective Time Period
Covered Countermeasures obtained
for the Strategic Nations Stockpile (SNS)
during the effective period of this
Declaration are covered through the date
of administration or use pursuant to a
distribution or release from the SNS.
XIV. Countermeasures Injury
Compensation Program
42 U.S.C 247d–6e
The PREP Act authorizes the
Countermeasures Injury Compensation
Program (CICP) to provide benefits to
certain individuals or estates of
individuals who sustain a covered
serious physical injury as the direct
result of the administration or use of the
Covered Countermeasures, and benefits
to certain survivors of individuals who
die as a direct result of the
administration or use of the Covered
Countermeasures. The causal
connection between the countermeasure
and the serious physical injury must be
supported by compelling, reliable, valid,
medical and scientific evidence in order
for the individual to be considered for
compensation. The CICP is
administered by the Health Resources
and Services Administration, within the
Department of Health and Human
Services. Information about the CICP is
available at the toll-free number 1–855–
266–2427 or https://www.hrsa.gov/cicp/.
Dated: February 6, 2017.
Norris Cochran,
Acting Secretary of Health and Human
Services.
XIII. Additional Time Period of
Coverage
mstockstill on DSK3G9T082PROD with NOTICES
42 U.S.C. 247d–6d(b)(2)(B)
Liability immunity for Covered
Countermeasures through means of
distribution, as identified in Section
VII(a) of this Declaration, other than in
accordance with the public health and
medical response of the Authority
Having Jurisdiction and extends for 24
months from the effective date of this
Declaration.
Liability immunity for Covered
Countermeasures administered and
used in accordance with the public
health and medical response of the
Authority Having Jurisdiction begins
with a Declaration and lasts through (1)
the final day the emergency Declaration
is in effect, or (2) 24 months from the
effective date of this Declaration,
whichever occurs first.
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
42 U.S.C. 247d–6d(b)(3)(B) and (C)
I have determined that an additional
12 months of liability protection is
reasonable to allow for the
manufacturer(s) to arrange for
disposition of the Covered
Countermeasure, including return of the
Covered Countermeasures to the
manufacturer, and for Covered Persons
to take such other actions as are
appropriate to limit the administration
or use of the Covered Countermeasures.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
VerDate Sep<11>2014
18:35 Feb 09, 2017
Jkt 241001
XV. Amendments
42 U.S.C. 247d–6d(b)(4)
Amendments to this Declaration will
be published in the Federal Register.
Authority: 42 U.S.C. 247d–6d.
[FR Doc. 2017–02778 Filed 2–9–17; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
PO 00000
Frm 00043
Fmt 4703
Sfmt 9990
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI CLTR SEP Review.
Date: March 3, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Chang Sook Kim, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7188, Bethesda, MD 20892–7924, 301–827–
7940, carolko@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Career Development Program to Promote
Diversity in Health Research.
Date: March 3, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: YingYing Li-Smerin, MD,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, 6701 Rockledge
Drive, Room 7184, Bethesda, MD 20892–
7924, 301–827–7942, lismerin@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Cystic Fibrosis Transmembrane Conductance
Regulator—Directed Therapeutics.
Date: March 3, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge Two, 7185, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Room 7185, Bethesda,
MD 20892, 301–827–7953, kristen.page@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: February 6, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–02723 Filed 2–9–17; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\10FEN1.SGM
10FEN1
]]>Agencies
[Federal Register Volume 82, Number 27 (Friday, February 10, 2017)]
[Notices]
[Page 10370]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02723]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; NHLBI CLTR SEP Review.
Date: March 3, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy
Chase, MD 20815.
Contact Person: Chang Sook Kim, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7188, Bethesda, MD
20892-7924, 301-827-7940, carolko@mail.nih.gov.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Career Development Program to Promote
Diversity in Health Research.
Date: March 3, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda,
MD 20814.
Contact Person: YingYing Li-Smerin, MD, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7184, Bethesda, MD
20892-7924, 301-827-7942, lismerin@nhlbi.nih.gov.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Cystic Fibrosis Transmembrane Conductance
Regulator--Directed Therapeutics.
Date: March 3, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge Two, 7185, 6701
Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D., Scientific Review Officer,
Office of Scientific Review/DERA, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, 301-827-7953, kristen.page@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: February 6, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-02723 Filed 2-9-17; 8:45 am]
BILLING CODE 4140-01-P
